These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1193 related items for PubMed ID: 27845907

  • 1. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
    Zhang B, Hu Y, Xiong RH, Pan YF, Xu QL, Kong XY, Cai R, Chen QQ, Tang HY, Jiang W.
    Oncotarget; 2017 Feb 21; 8(8):14078-14088. PubMed ID: 27845907
    [Abstract] [Full Text] [Related]

  • 2. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z, Zhang Z, Luo J, Li N, Peng X.
    J Cancer Res Clin Oncol; 2019 Jul 21; 145(7):1857-1864. PubMed ID: 31062162
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM, Yang Q, Guo L, Mai HQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Qiu F, Sun R, Chen QY, Huang PY, Luo DH, Hua YJ, Wu YS, Lv X, Wang L, Xia WX, Tang LQ, Ye YF, Chen MY, Guo X, Hong MH.
    Eur J Cancer; 2017 Apr 21; 75():14-23. PubMed ID: 28214653
    [Abstract] [Full Text] [Related]

  • 4. Induction Chemotherapy Followed by Radiotherapy versus Concurrent Chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis.
    Zeng Q, Wang J, Lv X, Li J, Yin LJ, Xiang YQ, Guo X.
    BMC Cancer; 2016 Aug 30; 16(1):693. PubMed ID: 27577729
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ, Huang PY, Shi JL, Xia HQ, Zhao C, Cao KJ.
    Chin J Cancer; 2016 Jan 06; 35():2. PubMed ID: 26739148
    [Abstract] [Full Text] [Related]

  • 6. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
    Yang Q, Cao SM, Guo L, Hua YJ, Huang PY, Zhang XL, Lin M, You R, Zou X, Liu YP, Xie YL, Wang ZQ, Mai HQ, Chen QY, Tang LQ, Mo HY, Cao KJ, Qian CN, Zhao C, Xiang YQ, Zhang XP, Lin ZX, Li WX, Liu Q, Li JB, Ling L, Guo X, Hong MH, Chen MY.
    Eur J Cancer; 2019 Sep 06; 119():87-96. PubMed ID: 31425966
    [Abstract] [Full Text] [Related]

  • 7. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW.
    Ann Oncol; 2018 Sep 01; 29(9):1972-1979. PubMed ID: 30016391
    [Abstract] [Full Text] [Related]

  • 8. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z, Cai Z, Cai Q, Hong Y, Zhang C, Huang K, Lin Z, Li M.
    Cancer Med; 2021 Jun 01; 10(12):3886-3895. PubMed ID: 33955190
    [Abstract] [Full Text] [Related]

  • 9. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study.
    Liu L, Fei Z, Chen M, Zhao L, Su H, Gu D, Lin B, Cai X, Lu L, Gao M, Ye X, Jin X, Xie C.
    Radiat Oncol; 2018 Aug 13; 13(1):148. PubMed ID: 30103765
    [Abstract] [Full Text] [Related]

  • 10. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Zhang J, Chen S, Li G, Zhang W, Qin T, Yin P, Huang H, Jiang H.
    Cancer Chemother Pharmacol; 2017 Jun 13; 79(6):1087-1097. PubMed ID: 28429051
    [Abstract] [Full Text] [Related]

  • 11. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
    Guo SS, Tang LQ, Chen QY, Zhang L, Liu LT, Guo L, Mo HY, Luo DH, Huang PY, Xiang YQ, Sun R, Chen MY, Wang L, Lv X, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Bei JX, Hong MH, Shao JY, Sun Y, Ma J, Mai HQ.
    Oncotarget; 2016 May 17; 7(20):29739-48. PubMed ID: 27105538
    [Abstract] [Full Text] [Related]

  • 12. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
    Li Y, Tang LQ, Liu LT, Guo SS, Liang YJ, Sun XS, Tang QN, Bei JX, Tan J, Chen S, Ma J, Zhao C, Chen QY, Mai HQ.
    Cancer Res Treat; 2018 Oct 17; 50(4):1304-1315. PubMed ID: 29334605
    [Abstract] [Full Text] [Related]

  • 13. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY, Lv X, Wu YS, Mao MJ, Ye YF, Yu YH, Liang H, Yang J, Ke LR, Qiu WZ, Huang XJ, Li WZ, Guo X, Xiang YQ, Xia WX.
    Cancer Commun (Lond); 2018 May 10; 38(1):21. PubMed ID: 29764487
    [Abstract] [Full Text] [Related]

  • 14. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW, Wang H, Liu ML, Zhang HB, Xiang YQ, Lv X, Xia WX, Zeng MS, Mai HQ, Hong MH, Guo X.
    Med Oncol; 2013 Mar 10; 30(1):322. PubMed ID: 23254962
    [Abstract] [Full Text] [Related]

  • 15. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW, Zou XB, Xiao Y, Tang J, OuYang PY, Su Z, Xie FY.
    PLoS One; 2016 Mar 10; 11(8):e0160758. PubMed ID: 27509025
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ, Hong MH.
    Oral Oncol; 2012 Oct 10; 48(10):1038-1044. PubMed ID: 22591726
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C, Sun R, Tang LL, Chen L, Li WF, Mao YP, Zhou GQ, Guo R, Lin AH, Sun Y, Ma J, Hu WH.
    Oral Oncol; 2018 Mar 10; 78():37-45. PubMed ID: 29496056
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R, Zhu J, Chen X, Liu Y, Wang Y, Zhang T.
    Clin Transl Oncol; 2020 Mar 10; 22(3):429-439. PubMed ID: 31165410
    [Abstract] [Full Text] [Related]

  • 20. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
    Ou D, Blanchard P, El Khoury C, De Felice F, Even C, Levy A, Nguyen F, Janot F, Gorphe P, Deutsch E, Temam S, Tao Y.
    Oral Oncol; 2016 Nov 10; 62():114-121. PubMed ID: 27865364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.